Spots Global Cancer Trial Database for cabazitaxel (xrp6258)
Every month we try and update this database with for cabazitaxel (xrp6258) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT01718353 | Prostate Cancer... | DOCETAXEL (XRP6... CABAZITAXEL (XR... Prednisone | 18 Years - | Sanofi | |
| Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer | NCT01576029 | Prostatic Neopl... | CABAZITAXEL (XR... DOCETAXEL (XRP6... | 18 Years - | Sanofi | |
| Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT01308580 | Prostate Cancer | Cabazitaxel (XR... Prednisone (or ... | 18 Years - | Sanofi | |
| Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer | NCT01308567 | Prostate Cancer | Cabazitaxel (XR... Docetaxel (XRP6... Prednisone | 18 Years - | Sanofi | |
| Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT01308580 | Prostate Cancer | Cabazitaxel (XR... Prednisone (or ... | 18 Years - | Sanofi | |
| Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT01308580 | Prostate Cancer | Cabazitaxel (XR... Prednisone (or ... | 18 Years - | Sanofi | |
| Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment | NCT01140607 | Neoplasm Malign... | Cabazitaxel (XR... | 18 Years - 60 Years | Sanofi | |
| Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer | NCT01324583 | Prostate Cancer | Cabazitaxel (XR... prednisolone | 20 Years - 73 Years | Sanofi | |
| Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer | NCT01649635 | Prostate Cancer | CABAZITAXEL (XR... Prednisone Ciprofloxacin G-CSF (Granuloc... | 18 Years - | Sanofi | |
| Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer | NCT01576029 | Prostatic Neopl... | CABAZITAXEL (XR... DOCETAXEL (XRP6... | 18 Years - | Sanofi | |
| A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors | NCT01755390 | Advanced Solid ... | Cabazitaxel (XR... | 18 Years - 70 Years | Sanofi | |
| Effect of Cabazitaxel on the QTc Interval in Cancer Patients | NCT01087021 | Neoplasms, Mali... | Cabazitaxel (XR... | 18 Years - | Sanofi | |
| Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer | NCT01576029 | Prostatic Neopl... | CABAZITAXEL (XR... DOCETAXEL (XRP6... | 18 Years - | Sanofi | |
| Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer | NCT01324583 | Prostate Cancer | Cabazitaxel (XR... prednisolone | 20 Years - 73 Years | Sanofi | |
| Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors | NCT01751308 | Malignant Solid... | Cabazitaxel (XR... | 2 Years - 18 Years | Sanofi | |
| Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer | NCT01308567 | Prostate Cancer | Cabazitaxel (XR... Docetaxel (XRP6... Prednisone | 18 Years - | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
